Barclays lowered shares of Hikma Pharmaceuticals (LON:HIK – Get Rating) to an equal weight rating in a research note released on Friday morning, MarketBeat Ratings reports. Barclays currently has GBX 1,750 ($21.44) price objective on the stock, down from their prior price objective of GBX 2,250 ($27.57).
A number of other equities research analysts have also recently weighed in on HIK. JPMorgan Chase & Co. cut shares of Hikma Pharmaceuticals to a neutral rating and dropped their price target for the company from GBX 2,900 ($35.53) to GBX 1,900 ($23.28) in a research report on Wednesday, May 25th. Morgan Stanley reiterated an equal weight rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, May 11th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of Hold and a consensus price target of GBX 2,291.67 ($28.08).
Hikma Pharmaceuticals Price Performance
Shares of HIK opened at GBX 1,604.50 ($19.66) on Friday. Hikma Pharmaceuticals has a 1-year low of GBX 1,459.50 ($17.88) and a 1-year high of GBX 2,674 ($32.77). The stock has a market cap of £3.53 billion and a PE ratio of 1,084.12. The firm has a 50-day simple moving average of GBX 1,649.71 and a two-hundred day simple moving average of GBX 1,851.18. The company has a debt-to-equity ratio of 34.29, a current ratio of 2.06 and a quick ratio of 1.31.
Hikma Pharmaceuticals Cuts Dividend
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.